NCT00947115 2020-10-30
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
Clinical Trials
4 trialsNCT00877877 2020-01-18
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
GlaxoSmithKline
Phase 3 Completed
NCT00929526 2016-10-20
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study
GlaxoSmithKline
Phase 3 Completed
NCT02100618 2015-07-20
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
GlaxoSmithKline
Phase 3 Withdrawn